Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An expanded access program to investigate the combination of lumacaftor and ivacaftor in patients with severe lung disease

Next Previous
Search
Trial Profile

An expanded access program to investigate the combination of lumacaftor and ivacaftor in patients with severe lung disease

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Nov 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivacaftor (Primary) ; Ivacaftor/lumacaftor (Primary) ; Lumacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Nov 2014 New trial record
    • 05 Nov 2014 According to a Vertex Pharmaceuticals media release, the company plans to begin this trial for a limited number of people in the second quarter of 2015, pending discussion with the FDA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top